JUST IN: SCIENTISTS DISCOVER LONG-TERM VIRAL SUPPRESSION IN HIV INFECTION

A new generation of broadly neutralising antibodies provides a novel approach to treating Human Immuno-deficiency Virus (HIV) infection.
The research group of Prof Florian Klein, Director of the Institute of Virology at the University Hospital Cologne and scientist at the German Center for Infection Research (DZIF), has collaborated with scientists at the Rockefeller University in New York and the University Hospital Cologne to investigate the impact of combining such antibodies in HIV-infected patients.

Two articles on the results of this clinical trial have now been published in Nature and Nature Medicine.Antiretroviral drugs are the critical component for effective management of HIV infection. Because of the rapid development of viral resistance against single agents, these drugs need to be administered in combination. While the currently approved drugs are highly active inhibitors of viral replication, they require daily and life-long dosing.

Compared to antiretroviral drugs, broadly neutralising antibodies have longer half-lives and can directly target the virus. In previous clinical trials conducted with participation of the University Hospital Cologne, two of these antibodies, called 3BNC117 and 10-1074, were administered individually. Both antibodies were well tolerated and resulted in significant reductions of the viral load. However, similar to treatment with classical antiretroviral drugs, the administration of a single antibody had only transient effects on the viral load and was associated with the development of viral resistance.

To receive more updates from Frayokit News, kindly SUBSCRIBE TO OUR NEWSLETTER or follow us on FACEBOOK and on TWITTER
For inquiries, adverts placement and news tip off, kindly call +2348083720023, +2348073006684 or send us email on: obeyafriday@gmail.com
Add Frayokit News On BBM. Pin: 5C130E7E or add us on WhatsApp. WhatsApp number: 08083720023